David A. MacQueen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
David A. MacQueen has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- David J. Drobes
Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL 33612, USA
5 shared publications - Jared W. Young
Department of Psychiatry, University of California San Diego, San Diego, USA
4 shared publications Arpi Minassian
Department of Psychiatry, School of Medicine, University of California San Diego, 9500 Gilman Drive MC 0804, La Jolla, CA, 92093-0804, USA; Center for Stress and Mental Health (CESAMH), VA San Diego Healthcare System, San Diego, CA, USA
3 shared publications- Bryan W. Heckman
Department of Psychiatry and Behavioral Sciences
3 shared publications Mark A. Geyer
Department of Psychiatry, School of Medicine, University of California San Diego, 9500 Gilman Drive MC 0804, La Jolla, CA, 92093-0804, USA; Research Service, VA San Diego Healthcare System, San Diego, CA, USA
3 shared publicationsMelissa D. Blank
Department of Health Outcomes and Behavior, Moffitt Cancer Center
3 shared publications
Latest Publications
- Open Access
- 25 February 2026
- Published by Elsevier in Journal of Substance Use and Addiction Treatment
- Vol. 185, 209927
The use of cellphone based automated pupillometry to quantify opioid withdrawal in patients receiving treatment for opioid use disorder
- 25 February 2026
- Published by Elsevier in Journal of Substance Use and Addiction Treatment
- Vol. 185, 209927
Open AccessThe use of cellphone based automated pupillometry to quantify opioid withdrawal in patients receiving treatment for opioid use disorder
- 26 September 2025
- Published by Springer Nature in Sleep and Biological Rhythms
- Vol. 24 (1) , 49-58
A double-blind, placebo-controlled investigation of the acute effects of Essence ring aromatherapy on sleep using actigraphy
Aromatherapy may represent a low-cost intervention for disturbed sleep that presents minimal risks as compared with alternative pharmacotherapies. Confirmation of effectiveness and an understanding of the mechanism of action are necessary to support clinical applications. The present study evaluated the impact of two odorants (lavender and peppermint) on sleep behavior using a double-blinded, placebo-controlled design. Consistent with the marketed aromatherapy uses of these odorants, lavender was expected to improve sleep while peppermint was expected to enhance arousal and disrupt sleep. Fifty-nine undergraduate students completed two sleep sessions, 1 week apart, during which active or placebo aromatherapy was initiated at their intended sleep time. A wrist-worn tracking device was used to quantify sleep behavior in their typical sleep environment. Both lavender and peppermint aromatherapy significantly disrupted sleep relative to placebo as measured by reduced minutes asleep, F = 5.65(1, 59), p < 0.02, and sleep efficiency F = 5.59(1, 59), p < 0.02. However, peppermint produced significantly greater disruption than lavender, consistent with its purported arousal-enhancing properties. To the extent that lavender aromatherapy improves sleep, repeated applications may be required, establishing lavender as a sleep cue. It is hypothesized that the more substantial disruption of sleep caused by peppermint may result from activation of the trigeminal nerve upon inhalation.
- 26 September 2025
- Published by Springer Nature in Sleep and Biological Rhythms
- Vol. 24 (1) , 49-58
A double-blind, placebo-controlled investigation of the acute effects of Essence ring aromatherapy on sleep using actigraphy
Aromatherapy may represent a low-cost intervention for disturbed sleep that presents minimal risks as compared with alternative pharmacotherapies. Confirmation of effectiveness and an understanding of the mechanism of action are necessary to support clinical applications. The present study evaluated the impact of two odorants (lavender and peppermint) on sleep behavior using a double-blinded, placebo-controlled design. Consistent with the marketed aromatherapy uses of these odorants, lavender was expected to improve sleep while peppermint was expected to enhance arousal and disrupt sleep. Fifty-nine undergraduate students completed two sleep sessions, 1 week apart, during which active or placebo aromatherapy was initiated at their intended sleep time. A wrist-worn tracking device was used to quantify sleep behavior in their typical sleep environment. Both lavender and peppermint aromatherapy significantly disrupted sleep relative to placebo as measured by reduced minutes asleep, F = 5.65(1, 59), p < 0.02, and sleep efficiency F = 5.59(1, 59), p < 0.02. However, peppermint produced significantly greater disruption than lavender, consistent with its purported arousal-enhancing properties. To the extent that lavender aromatherapy improves sleep, repeated applications may be required, establishing lavender as a sleep cue. It is hypothesized that the more substantial disruption of sleep caused by peppermint may result from activation of the trigeminal nerve upon inhalation.
- 16 April 2024
- Published by Elsevier in Behavioural Brain Research
- Vol. 467, 114991
Increased sensitivity in detection of deficits following two commonly used animal models of stroke
- 16 April 2024
- Published by Elsevier in Behavioural Brain Research
- Vol. 467, 114991
Increased sensitivity in detection of deficits following two commonly used animal models of stroke
- 5 September 2022
- Published by Springer Nature
- Vol. 63, 363-392
Olfactory Dysfunction in Schizophrenia: Evaluating Olfactory Abilities Across Species
Though understudied relative to perturbations in the auditory and visual domains, olfactory dysfunction is a common symptom of schizophrenia. Over the past two decades, the availability of standardized assessments to quantify human olfactory abilities, and enhance understanding of the neurophysiology supporting olfaction, has increased, enabling a more thorough characterization of these deficits. In contrast to other psychiatric conditions for which olfactory dysfunction has been observed (e.g., major depressive disorder, bipolar disorder, Alzheimer’s disease), the impairments observed in schizophrenia are particularly global and profound. At this level, such deficits in olfactory abilities likely impact the enjoyment of food, detection of environmental hazards, and influence social relationships. More broadly, the study of olfactory phenotypes in schizophrenia presents new avenues for detection of those at-risk for the condition, identification of therapeutic targets for treatment development, and for the characterization of novel animal models relevant to schizophrenia and psychosis. This review will consider the olfactory performance of individuals with schizophrenia in domains for which standardized assessments are available (odor sensitivity, discrimination, identification, and memory). Paradigms available for assessing these abilities in rodents will also be discussed with the aim of facilitating translation. Thus, future studies will be able to include cross-species translation of mechanisms relevant to olfactory function and cognition, what has gone awry in the disease state, and test potential therapeutics. Keywords Odor discrimination Odor identification Odor memory Odor sensitivity Odor threshold Olfaction Schizophrenia
- 5 September 2022
- Published by Springer Nature
- Vol. 63, 363-392
Olfactory Dysfunction in Schizophrenia: Evaluating Olfactory Abilities Across Species
Though understudied relative to perturbations in the auditory and visual domains, olfactory dysfunction is a common symptom of schizophrenia. Over the past two decades, the availability of standardized assessments to quantify human olfactory abilities, and enhance understanding of the neurophysiology supporting olfaction, has increased, enabling a more thorough characterization of these deficits. In contrast to other psychiatric conditions for which olfactory dysfunction has been observed (e.g., major depressive disorder, bipolar disorder, Alzheimer’s disease), the impairments observed in schizophrenia are particularly global and profound. At this level, such deficits in olfactory abilities likely impact the enjoyment of food, detection of environmental hazards, and influence social relationships. More broadly, the study of olfactory phenotypes in schizophrenia presents new avenues for detection of those at-risk for the condition, identification of therapeutic targets for treatment development, and for the characterization of novel animal models relevant to schizophrenia and psychosis. This review will consider the olfactory performance of individuals with schizophrenia in domains for which standardized assessments are available (odor sensitivity, discrimination, identification, and memory). Paradigms available for assessing these abilities in rodents will also be discussed with the aim of facilitating translation. Thus, future studies will be able to include cross-species translation of mechanisms relevant to olfactory function and cognition, what has gone awry in the disease state, and test potential therapeutics. Keywords Odor discrimination Odor identification Odor memory Odor sensitivity Odor threshold Olfaction Schizophrenia
- 28 April 2022
- Published by Elsevier in Biological Psychiatry
- Vol. 91 (9) , S5-S6
Mice With Reduced Sp4 Expression Exhibit Diminished Effortful Motivation, Exacerbated by Treatment With the Dopamine D2-Family Agonist Bromocriptine
- 28 April 2022
- Published by Elsevier in Biological Psychiatry
- Vol. 91 (9) , S5-S6
Mice With Reduced Sp4 Expression Exhibit Diminished Effortful Motivation, Exacerbated by Treatment With the Dopamine D2-Family Agonist Bromocriptine
- 1 August 2018
- Published by Elsevier in Neuropharmacology
- Vol. 138, 87-96
Amphetamine improves mouse and human attention in the 5-choice continuous performance test
- 1 August 2018
- Published by Elsevier in Neuropharmacology
- Vol. 138, 87-96
Amphetamine improves mouse and human attention in the 5-choice continuous performance test
- 16 October 2017
- Published by Cambridge University Press (CUP) in Journal of the International Neuropsychological Society
- Vol. 24 (3) , 283-293
Amphetamine Modestly Improves Conners’ Continuous Performance Test Performance in Healthy Adults
Objectives: Amphetamine improves vigilance as assessed by continuous performance tests (CPT) in children and adults with attention deficit hyperactivity disorder (ADHD). Less is known, however, regarding amphetamine effects on vigilance in healthy adults. Thus, it remains unclear whether amphetamine produces general enhancement of vigilance or if these effects are constrained to the remediation of deficits in patients with ADHD. Methods: We tested 69 healthy adults (35 female) on a standardized CPT (Conner’s CPT-2) after receiving 10- or 20-mg d-amphetamine or placebo. To evaluate potential effects on learning, impulsivity, and perseveration, participants were additionally tested on the Iowa Gambling Task (IGT) and Wisconsin Card Sorting Task (WCST). Results: Participants receiving placebo exhibited the classic vigilance decrement, demonstrated by a significant reduction in attention (D’) across the task. This vigilance decrement was not observed, however, after either dose of amphetamine. Consistent with enhanced vigilance, the 20-mg dose also reduced reaction time variability across the task and the ADHD confidence index. The effects of amphetamine appeared to be selective to vigilance since no effects were observed on the IGT, WCST, or response inhibition/perseveration measures from the CPT. Conclusions: The present data support the premise that amphetamine improves vigilance irrespective of disease state. Given that amphetamine is a norepinephrine/dopamine transporter inhibitor and releaser, these effects are informative regarding the neurobiological substrates of attentional control. (JINS, 2018, 24, 283–293)
- 16 October 2017
- Published by Cambridge University Press (CUP) in Journal of the International Neuropsychological Society
- Vol. 24 (3) , 283-293
Amphetamine Modestly Improves Conners’ Continuous Performance Test Performance in Healthy Adults
Objectives: Amphetamine improves vigilance as assessed by continuous performance tests (CPT) in children and adults with attention deficit hyperactivity disorder (ADHD). Less is known, however, regarding amphetamine effects on vigilance in healthy adults. Thus, it remains unclear whether amphetamine produces general enhancement of vigilance or if these effects are constrained to the remediation of deficits in patients with ADHD. Methods: We tested 69 healthy adults (35 female) on a standardized CPT (Conner’s CPT-2) after receiving 10- or 20-mg d-amphetamine or placebo. To evaluate potential effects on learning, impulsivity, and perseveration, participants were additionally tested on the Iowa Gambling Task (IGT) and Wisconsin Card Sorting Task (WCST). Results: Participants receiving placebo exhibited the classic vigilance decrement, demonstrated by a significant reduction in attention (D’) across the task. This vigilance decrement was not observed, however, after either dose of amphetamine. Consistent with enhanced vigilance, the 20-mg dose also reduced reaction time variability across the task and the ADHD confidence index. The effects of amphetamine appeared to be selective to vigilance since no effects were observed on the IGT, WCST, or response inhibition/perseveration measures from the CPT. Conclusions: The present data support the premise that amphetamine improves vigilance irrespective of disease state. Given that amphetamine is a norepinephrine/dopamine transporter inhibitor and releaser, these effects are informative regarding the neurobiological substrates of attentional control. (JINS, 2018, 24, 283–293)
- 1 October 2017
- Published by Elsevier in Neuropharmacology
- Vol. 125, 254-262
Modafinil improves attentional performance in healthy, non-sleep deprived humans at doses not inducing hyperarousal across species
- 1 October 2017
- Published by Elsevier in Neuropharmacology
- Vol. 125, 254-262
Modafinil improves attentional performance in healthy, non-sleep deprived humans at doses not inducing hyperarousal across species
- 14 July 2017
- Published by Springer Nature in Psychopharmacology
- Vol. 234 (19) , 2871-2882
Validation of the human odor span task: effects of nicotine
Rationale Amongst non-smokers, nicotine generally enhances performance on tasks of attention, with limited effect on working memory. In contrast, nicotine has been shown to produce robust enhancements of working memory in non-humans. Objectives To address this gap, the present study investigated the effects of nicotine on the performance of non-smokers on a cognitive battery which included a working memory task reverse-translated from use with rodents (the odor span task, OST). Nicotine has been reported to enhance OST performance in rats and the present study assessed whether this effect generalizes to human performance. Methods Thirty non-smokers were tested on three occasions after consuming either placebo, 2 mg, or 4 mg nicotine gum. On each occasion, participants completed a battery of clinical and experimental tasks of working memory and attention. Results Nicotine was associated with dose-dependent enhancements in sustained attention, as evidenced by increased hit accuracy on the rapid visual information processing (RVIP) task. However, nicotine failed to produce main effects on OST performance or on alternative measures of working memory (digit span, spatial span, letter-number sequencing, 2-back) or attention (digits forward, 0-back). Interestingly, enhancement of RVIP performance occurred concomitant to significant reductions in self-reported attention/concentration. Human OST performance was significantly related to N-back performance, and as in rodents, OST accuracy declined with increasing memory load. Conclusions Given the similarity of human and rodent OST performance under baseline conditions and the strong association between OST and visual 0-back accuracy, the OST may be particular useful in the study of conditions characterized by inattention.
- 14 July 2017
- Published by Springer Nature in Psychopharmacology
- Vol. 234 (19) , 2871-2882
Validation of the human odor span task: effects of nicotine
Rationale Amongst non-smokers, nicotine generally enhances performance on tasks of attention, with limited effect on working memory. In contrast, nicotine has been shown to produce robust enhancements of working memory in non-humans. Objectives To address this gap, the present study investigated the effects of nicotine on the performance of non-smokers on a cognitive battery which included a working memory task reverse-translated from use with rodents (the odor span task, OST). Nicotine has been reported to enhance OST performance in rats and the present study assessed whether this effect generalizes to human performance. Methods Thirty non-smokers were tested on three occasions after consuming either placebo, 2 mg, or 4 mg nicotine gum. On each occasion, participants completed a battery of clinical and experimental tasks of working memory and attention. Results Nicotine was associated with dose-dependent enhancements in sustained attention, as evidenced by increased hit accuracy on the rapid visual information processing (RVIP) task. However, nicotine failed to produce main effects on OST performance or on alternative measures of working memory (digit span, spatial span, letter-number sequencing, 2-back) or attention (digits forward, 0-back). Interestingly, enhancement of RVIP performance occurred concomitant to significant reductions in self-reported attention/concentration. Human OST performance was significantly related to N-back performance, and as in rodents, OST accuracy declined with increasing memory load. Conclusions Given the similarity of human and rodent OST performance under baseline conditions and the strong association between OST and visual 0-back accuracy, the OST may be particular useful in the study of conditions characterized by inattention.